1
00:00:00,000 --> 00:00:03,600
Weekly tirzepatide lowered BMI by 18.5% in

2
00:00:03,600 --> 00:00:07,233
adolescents over 72 weeks.

3
00:00:07,233 --> 00:00:09,800
SURMOUNT-ADOLESCENTS was a phase 3,

4
00:00:09,800 --> 00:00:12,567
double-blind trial of 160 adolescents with

5
00:00:12,567 --> 00:00:15,000
obesity or overweight with at least 1

6
00:00:15,000 --> 00:00:18,167
obesity-related complication.

7
00:00:18,167 --> 00:00:22,400
BMI fell by 18.5% with tirzepatide and rose

8
00:00:22,400 --> 00:00:25,467
by 0.5% with placebo.

9
00:00:25,467 --> 00:00:29,700
At least a 5% BMI fall was reached by 79.6%

10
00:00:29,700 --> 00:00:35,100
on tirzepatide versus 28.5% on placebo.

11
00:00:35,100 --> 00:00:37,633
Gastrointestinal events were most common,

12
00:00:37,633 --> 00:00:39,567
mostly mild to moderate.

13
00:00:39,567 --> 00:00:42,100
The trial was modest in size, and growth,

14
00:00:42,100 --> 00:00:44,533
puberty and longer-term data are not in the

15
00:00:44,533 --> 00:00:46,167
abstract.

16
00:00:46,167 --> 00:00:48,700
The full report, its source and a free

17
00:00:48,700 --> 00:00:52,700
teaching slide are at diabesityrounds.com.
